Patient-reported Outcomes from TITAN: Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer – Neeraj Agarwal

In this conversation, Neeraj Agarwal joins Petros Grivas to discuss the Patient-Reported Outcomes (PRO) data from the TITAN study, Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. This data was presented at ESMO 2019. The Food and Drug Administration approved apalutamide (ERLEADA, Janssen Biotech, Inc) for patients with metastatic hormone-sensitive prostate cancer. (mHSPC) in…

Read the full article here

Source: UroToday

Categories: Urology

Tags: TITAN

Tweets with this article

UroToday.com

#TITAN Patient-reported outcomes - Apalutamide for mCSPC - Discussion by @neerajaiims @UofUMedicine @huntsmancancer and @PGrivasMDPhD @UW. #ListenNow on UroToday > https://t.co/gNHpGF7UAW @NEJM @JanssenGlobal https://t.co/AXN3VC9FF8

Welcome! You are invited to join a webinar: PCF Virtual Patient & Caregiver Summit: Advanced Prostate Cancer. After registering, you will receive a confirmation email about joining the webinar.

Please join us for a PCF Virtual Patient & Caregiver Summit on Advanced Prostate Cancer. Learn about the latest developments in treatment for advanced prostate…

UroToday.com October 4, 2024

Novel CD40 Antibody Treatment for BCG-Unresponsive Bladder Cancer – Bernard Bochner

Sam Chang and Bernard Bochner discuss a novel antibody treatment targeting the CD40 receptor for non-muscle invasive bladder cancer resistant to BCG therapy. Dr. Bochner…

UroToday.com October 4, 2024

The Adrenal Permissive HSD3B1 Allele: A Decade-Long Journey from Initial Discovery to Proven Clinical Significance in Prostate Cancer – Nima Sharifi

Alicia Morgans and Nima Sharifi discuss the role of the HSD3B1 gene and its variants in prostate cancer. Dr. Sharifi explains that the adrenal permissive…

UroToday.com October 4, 2024

Related Articles